Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.

Liu Y, Zhu YH, Mao CQ, Dou S, Shen S, Tan ZB, Wang J.

J Control Release. 2014 Oct 28;192:114-21. doi: 10.1016/j.jconrel.2014.07.001.

PMID:
25016158
2.

Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.

Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J.

J Control Release. 2011 Dec 10;156(2):203-11. doi: 10.1016/j.jconrel.2011.07.035.

PMID:
21839126
3.

Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.

Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.

Breast Cancer Res. 2015;17:19. doi: 10.1186/s13058-015-0524-0.

4.

"Triple-punch" strategy for triple negative breast cancer therapy with minimized drug dosage and improved antitumor efficacy.

Su S, Tian Y, Li Y, Ding Y, Ji T, Wu M, Wu Y, Nie G.

ACS Nano. 2015 Feb 24;9(2):1367-78. doi: 10.1021/nn505729m.

PMID:
25611071
5.

ScFv-decorated PEG-PLA-based nanoparticles for enhanced siRNA delivery to Her2⁺ breast cancer.

Dou S, Yang XZ, Xiong MH, Sun CY, Yao YD, Zhu YH, Wang J.

Adv Healthc Mater. 2014 Nov;3(11):1792-803. doi: 10.1002/adhm.201400037.

PMID:
24947820
6.

Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.

Shu D, Li H, Shu Y, Xiong G, Carson WE 3rd, Haque F, Xu R, Guo P.

ACS Nano. 2015 Oct 27;9(10):9731-40. doi: 10.1021/acsnano.5b02471.

8.
9.

Delivery of bortezomib with nanoparticles for basal-like triple-negative breast cancer therapy.

Shen S, Du XJ, Liu J, Sun R, Zhu YH, Wang J.

J Control Release. 2015 Jun 28;208:14-24. doi: 10.1016/j.jconrel.2014.12.043.

PMID:
25575864
10.

Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.

Parvani JG, Gujrati MD, Mack MA, Schiemann WP, Lu ZR.

Cancer Res. 2015 Jun 1;75(11):2316-25. doi: 10.1158/0008-5472.CAN-14-3485.

11.

Polymer nanoparticles mediated codelivery of antimiR-10b and antimiR-21 for achieving triple negative breast cancer therapy.

Devulapally R, Sekar NM, Sekar TV, Foygel K, Massoud TF, Willmann JK, Paulmurugan R.

ACS Nano. 2015 Mar 24;9(3):2290-302. doi: 10.1021/nn507465d.

13.

Evaluation of cationic nanoparticles of biodegradable copolymers as siRNA delivery system for hepatitis B treatment.

Wang J, Feng SS, Wang S, Chen ZY.

Int J Pharm. 2010 Nov 15;400(1-2):194-200. doi: 10.1016/j.ijpharm.2010.08.026.

PMID:
20801205
14.

Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.

Gomes-da-Silva LC, Fonseca NA, Moura V, Pedroso de Lima MC, Simões S, Moreira JN.

Acc Chem Res. 2012 Jul 17;45(7):1163-71. doi: 10.1021/ar300048p.

PMID:
22568781
15.

Matrix metalloproteinase 2-responsive micelle for siRNA delivery.

Wang HX, Yang XZ, Sun CY, Mao CQ, Zhu YH, Wang J.

Biomaterials. 2014 Aug;35(26):7622-34. doi: 10.1016/j.biomaterials.2014.05.050.

PMID:
24929619
16.

PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells.

Plantamura I, Casalini P, Dugnani E, Sasso M, D'Ippolito E, Tortoreto M, Cacciatore M, Guarnotta C, Ghirelli C, Barajon I, Bianchi F, Triulzi T, Agresti R, Balsari A, Campiglio M, Tripodo C, Iorio MV, Tagliabue E.

Mol Oncol. 2014 Jul;8(5):968-81. doi: 10.1016/j.molonc.2014.03.015.

17.

Methoxy poly(ethylene glycol)-poly(lactide) nanoparticles encapsulating quercetin act as an effective anticancer agent by inducing apoptosis in breast cancer.

Sharma G, Park J, Sharma AR, Jung JS, Kim H, Chakraborty C, Song DK, Lee SS, Nam JS.

Pharm Res. 2015 Feb;32(2):723-35. doi: 10.1007/s11095-014-1504-2.

PMID:
25186442
18.

A biodegradable amphiphilic and cationic triblock copolymer for the delivery of siRNA targeting the acid ceramidase gene for cancer therapy.

Mao CQ, Du JZ, Sun TM, Yao YD, Zhang PZ, Song EW, Wang J.

Biomaterials. 2011 Apr;32(11):3124-33. doi: 10.1016/j.biomaterials.2011.01.006.

PMID:
21277018
19.

Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.

Ho EA, Osooly M, Strutt D, Masin D, Yang Y, Yan H, Bally M.

J Pharm Sci. 2013 Jan;102(1):227-36. doi: 10.1002/jps.23351.

PMID:
23132529
Items per page

Supplemental Content

Support Center